IDH1 and astrocytoma (excluding glioblastoma): A study published in the Journal of Clinical Neuroscience used human brain tumor samples and demonstrated that elevated 2-HG could be used as a biomarker of the IDH1/2 mutation status in gliomas, which would distinguish glioblastomas from astrocytomas and oligodendrogliomas [30].